Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients.

Next Previous
X
Search
Trial Profile

Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
  • Indications Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms JONIE 3

    • Most Recent Events

    • 14 Dec 2019 Results of randomized controlled trial of neoadjuvant eribulin mesylate versus paclitaxel in women with operable breast cancer has been presented at the 42nd Annual San Antonio Breast Cancer Symposium
    • 11 Jan 2018 New trial record
    • 09 Dec 2017 Results (n=121) presented at the 40th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top